@article {7939,
	title = {Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma},
	journal = {British Journal of Haematology},
	volume = {135},
	year = {2006},
	note = {Cited By :155Export Date: 21 February 2017},
	month = {2006},
	pages = {688 - 692},
	abstract = {The effect of bortezomib on bone remodelling was evaluated in 34 relapsed myeloma patients. At baseline, patients had increased serum concentrations of dickkopf-1 (DKK-1), soluble receptor activator of nuclear factor-κB ligand (sRANKL), sRANKL/osteoprotegerin ratio, C-telopeptide of type-I collagen (CTX) and tartrate-resistant acid phosphatase isoform-5b (TRACP-5b); bone-alkaline phosphatase and osteocalcin were reduced. Serum DKK-1 correlated with CTX and severe bone disease. Bortezomib administration significantly reduced serum DKK-1, sRANKL, CTX, and TRACP-5b after four cycles, and dramatically increased bone-alkaline phosphatase and osteocalcin, irrespective of treatment response. This is the first study showing that bortezomib reduces DKK-1 and RANKL serum levels, leading to the normalisation of bone remodelling in relapsed myeloma. {\textcopyright} 2006 The Authors.},
	keywords = {bone markers, bortezomib, Dickkopf-1, multiple myeloma, Receptor activator of nuclear factor-kappa B ligand},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750566914\&doi=10.1111\%2fj.1365-2141.2006.06356.x\&partnerID=40\&md5=6f3d0eb0ba7eb566e56bd72a8edfa77f},
	author = {Terpos, E. and Heath, D.J. and Rahemtulla, A. and Zervas, K. and Chantry, A. and Anagnostopoulos, A. and Pouli, A. and Katodritou, E. and Verrou, E. and Vervessou, E.-C. and Dimopoulos, M.-A. and Croucher, P.I.}
}
